|
Stoke Therapeutics, Inc. (STOK) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Stoke Therapeutics, Inc. (STOK) Bundle
¿Busca determinar el valor intrínseco de Stoke Therapeutics, Inc.? Nuestra calculadora STOK DCF integra datos del mundo real con extensas características de personalización, lo que le permite ajustar los pronósticos y mejorar su estrategia de inversión.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | 12.4 | 8.8 | 8.1 | 7.5 | 7.0 | 6.5 | 6.0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | -29.22 | -7.31 | -7.31 | -7.31 | -7.31 | -7.31 |
EBITDA | -35.2 | -50.3 | -83.6 | -102.8 | -112.3 | 1.6 | 1.5 | 1.4 | 1.3 | 1.2 |
EBITDA, % | 100 | 100 | 100 | -828.78 | -1279.09 | 20 | 20 | 20 | 20 | 20 |
Depreciation | .5 | 1.9 | 2.2 | 3.5 | 2.5 | 5.8 | 5.4 | 5.0 | 4.6 | 4.3 |
Depreciation, % | 100 | 100 | 100 | 28.5 | 28.12 | 71.32 | 71.32 | 71.32 | 71.32 | 71.32 |
EBIT | -35.7 | -52.2 | -85.8 | -106.3 | -114.8 | 1.6 | 1.5 | 1.4 | 1.3 | 1.2 |
EBIT, % | 100 | 100 | 100 | -857.28 | -1307.21 | 20 | 20 | 20 | 20 | 20 |
Total Cash | 222.5 | 287.3 | 219.8 | 229.6 | 201.4 | 8.1 | 7.5 | 7.0 | 6.5 | 6.0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .3 | .0 | .1 | .6 | .1 | 5.0 | 4.6 | 4.3 | 4.0 | 3.7 |
Account Receivables, % | 100 | 100 | 100 | 4.74 | 0.72893 | 61.09 | 61.09 | 61.09 | 61.09 | 61.09 |
Inventories | .0 | .0 | .0 | 10.9 | .0 | 6.3 | 5.9 | 5.4 | 5.0 | 4.7 |
Inventories, % | 100 | 100 | 100 | 88.13 | 0 | 77.63 | 77.63 | 77.63 | 77.63 | 77.63 |
Accounts Payable | .8 | 1.5 | 2.4 | .8 | 1.7 | 5.3 | 4.9 | 4.6 | 4.2 | 3.9 |
Accounts Payable, % | 100 | 100 | 100 | 6.17 | 19.31 | 65.1 | 65.1 | 65.1 | 65.1 | 65.1 |
Capital Expenditure | -1.6 | -1.1 | -1.2 | -4.0 | -1.6 | -.8 | -.8 | -.7 | -.7 | -.6 |
Capital Expenditure, % | 100 | 100 | 100 | -31.94 | -18.41 | -10.07 | -10.07 | -10.07 | -10.07 | -10.07 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -31.5 | -50.6 | -84.7 | -98.0 | -114.8 | 1.5 | 1.4 | 1.3 | 1.2 | 1.1 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -32.2 | -48.7 | -82.9 | -111.4 | -101.5 | -1.1 | 6.5 | 6.0 | 5.6 | 5.2 |
WACC, % | 8.9 | 8.91 | 8.91 | 8.9 | 8.91 | 8.9 | 8.9 | 8.9 | 8.9 | 8.9 |
PV UFCF | ||||||||||
SUM PV UFCF | 16.5 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 5 | |||||||||
Terminal Value | 76 | |||||||||
Present Terminal Value | 50 | |||||||||
Enterprise Value | 66 | |||||||||
Net Debt | -189 | |||||||||
Equity Value | 256 | |||||||||
Diluted Shares Outstanding, MM | 44 | |||||||||
Equity Value Per Share | 5.81 |
What You Will Get
- Comprehensive STOK Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Stoke Therapeutics’ future performance.
- User-Friendly Interface: Designed for professionals while remaining easy for newcomers.
Key Features
- Customizable Research Inputs: Adjust key variables such as revenue projections, R&D spending, and market penetration rates.
- Instant DCF Analysis: Automatically computes intrinsic value, NPV, and additional metrics in real-time.
- High-Precision Results: Leverages Stoke Therapeutics' actual financial data for accurate valuation assessments.
- Effortless Scenario Testing: Easily explore various assumptions and evaluate their impacts side by side.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- 1. Access the Template: Download and open the Excel file containing Stoke Therapeutics, Inc.'s preloaded data.
- 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
- 3. Observe Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Evaluate Scenarios: Analyze various forecasts to explore different valuation results.
- 5. Present with Assurance: Deliver professional valuation insights to guide your strategic decisions.
Why Choose This Calculator for Stoke Therapeutics, Inc. (STOK)?
- User-Friendly Interface: Tailored for both novices and seasoned professionals.
- Customizable Inputs: Adjust parameters effortlessly to suit your analysis needs.
- Real-Time Feedback: Monitor immediate changes to Stoke Therapeutics' valuation as you modify inputs.
- Pre-Configured Data: Comes with Stoke Therapeutics' actual financial metrics for swift evaluations.
- Relied Upon by Experts: Employed by investors and analysts for making well-informed decisions.
Who Should Use This Product?
- Investors: Accurately assess Stoke Therapeutics, Inc.'s (STOK) intrinsic value prior to making investment choices.
- CFOs: Utilize a sophisticated DCF model for financial reporting and strategic analysis.
- Consultants: Efficiently modify the template for client valuation reports.
- Entrepreneurs: Acquire insights into the financial modeling practices of leading biotech firms.
- Educators: Employ it as a resource to illustrate valuation techniques in the classroom.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring extensive valuation calculations.
- Real-World Data: Stoke Therapeutics’ historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Visualizations including charts and tables for clear, actionable results.